{"product_id":"asrgl1-antibody-bha17113623","title":"ASRGL1 Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eASRGL1 Antibody is a research-use primary antibody intended for detection of \u003cstrong\u003eASRGL1\u003c\/strong\u003e in experimental workflows. It is supplied in \u003cstrong\u003ePurified\u003c\/strong\u003e format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone CRASH\/1289, isotype Mouse IgG1, kappa. Applications listed for this product include IHC-P. Reported\/annotated localization context: Cytoplasmic, nuclear. Species reactivity (as provided): Human.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e ASRGL1 — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Mouse, Monoclonal (mouse origin), clone CRASH\/1289, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Cytoplasmic, nuclear — expected subcellular distribution can guide band\/structure interpretation and help flag off-target signal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct notes (from provided description):\u003c\/strong\u003e ASRGL1 (Asparaginase-like protein 1), also known as CRASH, belongs to the Ntn-hydrolase family. Asparaginases utilize asparagine as a substrate to produce aspartic acid and ammonia. ASRGL1 has been identified as a autoantigenic protein that is present in the mid-piece of sperm after obstruction of the male reproductive tract. It is expressed highly in testis, but is also expressed in brain, kidney and gastrointestinal tissues. High levels of ASRGL1 have also been identified in ovarian, uterine and mammary tumors in comparison with normal tissues of the same origin.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhere multiple assay formats are possible, align the antibody format, host\/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eIn this catalog, ASRGL1 is positioned within \u003cstrong\u003eRenal \u0026amp; Urology, Tumor, Kidney disease\u003c\/strong\u003e research contexts. Localization annotations (e.g., Cytoplasmic, nuclear) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene\/protein nomenclature, domains\/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eHigher-plex and spatially resolved readouts (e.g., multiplex IF\/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host\/isotype and labeling strategies.\u003c\/li\u003e\n\u003cli\u003eGenetic perturbation controls (knockout\/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.\u003c\/li\u003e\n\u003cli\u003eReproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.\u003c\/li\u003e\n\u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC-P:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical workflow themes:\u003c\/strong\u003e IHC on FFPE tissue, ELISA binding assay, Specificity controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkflow notes:\u003c\/strong\u003e Detect ASRGL1 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to ASRGL1 peptide\/protein by ELISA with dilution series (include blanks), Confirm specificity using KO\/KD or peptid…\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhen comparing conditions, consistent sample processing and appropriate negative\/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eIsoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.\u003c\/li\u003e\n\u003cli\u003eSpecies and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.\u003c\/li\u003e\n\u003cli\u003eControl concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic\/orthogonal controls (e.g., KO\/KD, independent antibodies, or RNA measurements) when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eMonoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt Knowledgebase (UniProtKB) — UniProt Consortium — https:\/\/www.uniprot.org\/ - NCBI Gene — National Center for Biotechnology Information (NCBI) — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - The Human Protein Atlas — Human Protein Atlas — https:\/\/www.proteinatlas.org\/ - Antibody validation concepts and controls (general guidance) — NIH \/ community resources — https:\/\/www.nih.gov\/ - MIQE\/experimental reporting \u0026 reproducibility (general) — Scientific community guidelines — https:\/\/www.equator-network.org\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 100 ug","offer_id":53044913504621,"sku":"V3230-100UG","price":559.0,"currency_code":"USD","in_stock":true},{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 20 ug","offer_id":53045027537261,"sku":"V3230-20UG","price":259.0,"currency_code":"USD","in_stock":true},{"title":"1 mg\/ml in 1X PBS; BSA free, sodium azide free \/ 100 ug","offer_id":53045027570029,"sku":"V3230SAF-100UG","price":559.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_64a7197a-c083-4cfb-9d10-b371c45f2043.jpg?v=1782236852","url":"https:\/\/www.ebiohippo.com\/products\/asrgl1-antibody-bha17113623","provider":"BioHippo","version":"1.0","type":"link"}